Compare NWTG & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | LYRA |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.6M |
| IPO Year | N/A | 2020 |
| Metric | NWTG | LYRA |
|---|---|---|
| Price | $1.85 | $4.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 173.3K | 95.9K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,931,000.00 | $600,000.00 |
| Revenue This Year | $120.41 | N/A |
| Revenue Next Year | $70.24 | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 178.24 | N/A |
| 52 Week Low | $0.82 | $2.84 |
| 52 Week High | $49.80 | $37.50 |
| Indicator | NWTG | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 51.94 |
| Support Level | $1.49 | $3.47 |
| Resistance Level | $1.75 | $4.16 |
| Average True Range (ATR) | 0.18 | 0.42 |
| MACD | 0.08 | 0.21 |
| Stochastic Oscillator | 91.02 | 95.25 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.